Skip to main content

Table 4 Frequency of Antidrug Antibody Activity

From: A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects

Time point (h)FKB327 vial
n = 66
n (%)
FKB327 PFS
n = 63
n (%)
FKB327 AI
n = 66
n (%)
NegativePositiveNegativePositiveNegativePositive
Predose52 (78.8)14 (21.2)51 (81.0)12 (19.0)59 (89.4)7 (10.6)
36013 (19.7)52 (78.8)29 (46.0)34 (54.0)25 (37.9)41 (62.1)
6964 (6.1)61 (92.4)4 (6.3)59 (93.7)4 (6.1)62 (93.9)
1536066 (100)a063 (100)1 (1.5)65 (98.5)
  1. aIncludes 1 early-withdrawal subject
  2. AI indicates prefilled autoinjector; PFS prefilled syringe; vial, vial with disposable syringe